NCBI PubMed ID:30873933 Publication DOI:10.1128/microbiolspec.GPP3-0001-2017 Journal NLM ID:101634614 Publisher: Washington, DC: ASM Press Correspondence: Lawrence C. Paoletti <lawrence_paolettihms.harvard.edu> Institutions: Division of Immunology, Department of Microbiology and Immunobiology, Harvard Medical School, Boston, MA 02115
The surface of the Gram-positive opportunistic pathogen Streptococcus agalactiae, or group B Streptococcus (GBS), harbors several carbohydrate and protein antigens with the potential to be effective vaccines. Capsular polysaccharides of all clinically-relevant GBS serotypes coupled to immunogenic proteins of both GBS and non-GBS origin have undergone extensive testing in animals that led to advanced clinical trials in healthy adult women. In addition, GBS proteins either alone or in combination have been tested in animals; a fusion protein construct has recently advanced to human clinical studies. Given our current understanding of the antigenicity and immunogenicity of the wide array of GBS surface antigens, formulations now exist for the generation of viable vaccines against diseases caused by GBS.
structure, capsular polysaccharides, group B Streptococcus, surface, vaccines, Streptococcus agalactiae, Gram-positive
Comments, role: review; fragment of the proposed structure; The group B carbohydrate is a cell wall-associated molecule common to all strains and serotypes of GBS.
Related record ID(s): 1086, 2235, 2236 NCBI Taxonomy refs (TaxIDs):1311, 1319 Reference(s) to other database(s): GTC:G51420AQ Show glycosyltransferases
There are 2 chemically distinct structures. Please, select:
Found 
report error
hms.harvard.edu>